Trudo Lemmens
- Pharmacology top 5%
- Pharmaceutical industry and healthcare 20
- Health top 5%
-
- Ethics in Clinical Research 34
- Palliative Care and End-of-Life Issues 6
- Modeling and Simulation top 5%
-
- Biomedical Ethics and Regulation 33
-
- Ethics in medical practice 13
-
- Health Systems, Economic Evaluations, Quality of Life 12
- Pharmaceutical Economics and Policy 7
-
- Intellectual Property and Patents 5
- Co-authors
- Carl ElliottBenjamin FreedmanRaymond De VriesEuzebiusz JamrozikSalmaan KeshavjeeKevin BardoshStefan BaralJanice Graham
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Trudo Lemmens
91 papers receiving 857 citations
Hit Papers
Peers
Comparison fields: 5 of 109
- Pharmacology 162
- Health 148
- Public Health, Environmental and Occupational Health 411
- Medical Terminology 3
- Modeling and Simulation 49
Countries citing papers authored by Trudo Lemmens
This map shows the geographic impact of Trudo Lemmens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Trudo Lemmens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Trudo Lemmens more than expected).
Fields of papers citing papers by Trudo Lemmens
This network shows the impact of papers produced by Trudo Lemmens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Trudo Lemmens. The network helps show where Trudo Lemmens may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Trudo Lemmens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than goodbreakdown → | 2022 | 175 |
| 2 | 2022 | 26 | |
| 3 | Why Canada's Medical Assistance in Dying Legislation Should Be C(h)arter Compliant and What It May Help to Avoid | 2018 | 4 |
| 4 | Transparency of Biobank Access in Canada: An Assessment of Industry Access and the Availability of Information on Access Policies and Resulting Research | 2017 | 1 |
| 5 | The Conflict between Open-Ended Access to Physician-Assisted Dying and the Protection of the Vulnerable: Lessons from Belgium's Euthanasia Regime for the Canadian Post-Carter Era | 2016 | 4 |
| 6 | The Promise and Peril of Adapting the Regulatory System to the Pharmacogenomic Context | 2015 | 1 |
| 7 | Regulation of Pharmaceuticals in Canada | 2012 | 3 |
| 8 | Analysis of Consent Validity for Invasive, Nondiagnostic Research Procedures | 2012 | 1 |
| 9 | Revisiting Genetic Discrimination Issues in 2010: Policy Options for Canada | 2010 | 2 |
| 10 | The FDA and the Declaration of Helsinki: A New Rule Seems to Be More About Imperialism than Harmonisation | 2009 | 2 |
| 11 | Research Involving Humans | 2009 | 2 |
| 12 | The End of Individual Control over Health Information: Promoting Fair Information Practices and the Governance of Biobank Research | 2009 | 1 |
| 13 | Data Collection from Legally Incompetent Subjects: A Paradigm Legal and Ethical Challenge for Population Databanks | 2008 | 2 |
| 14 | The Helsinki Declaration and the Law: An International and Comparative Analysis | 2007 | 3 |
| 15 | Insurance and human rights: what can Europe learn from Canadian anti-discrimination law? | 2007 | 3 |
| 16 | Genetics and Insurance Discrimination: Comparative Legislative, Regulatory and Policy Developments and Canadian Options | 2004 | 6 |
| 17 | CAN INSURANCE LAW ACCOMODATE THE UNCERTAINTY ASSOCIATED WITH PRELIMINARY GENETIC INFORMATION | 2004 | 1 |
| 18 | Genetics and life insurance in Canada: points to consider | 2003 | 6 |
| 19 | Genetic information and insurance : a contextual analysis of legal and regulatory means of promoting just distributions | 2003 | 1 |
| 20 | Ethical and policy issues of genetic testing in the workplace | 1995 | 1 |
About Trudo Lemmens
Trudo Lemmens is a scholar working on Pharmacology, Public Health, Environmental and Occupational Health and Physiology, having authored 96 papers that have together received 925 indexed citations. Recurring topics across this work include Ethics in Clinical Research (34 papers), Biomedical Ethics and Regulation (33 papers), Pharmaceutical industry and healthcare (20 papers), Ethics in medical practice (13 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers), Pharmaceutical Economics and Policy (7 papers), Palliative Care and End-of-Life Issues (6 papers) and Intellectual Property and Patents (5 papers). The work is most often cited by research in Pharmacology (162 citations), Health (148 citations) and Public Health, Environmental and Occupational Health (411 citations). Trudo Lemmens has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Carl Elliott, Benjamin Freedman, Raymond De Vries, Euzebiusz Jamrozik, Salmaan Keshavjee, Kevin Bardosh, Stefan Baral, Janice Graham, Peter Singer and Alexandre de Figueiredo. Their work appears in journals such as Social Science & Medicine, BMJ and PLoS Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.